Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023 in San Francisco, CA. Glaukos will be exhibiting onsite at booth #1630.

Key Glaucoma Presentations:

Saturday, November 4, 2023, at 10:00 – 10:30 a.m. PT

• Jason Bacharach, MD
  IOP at Month 3 with Travoprost Intraocular Implant vs. IOP at Screening While on Prostaglandin Analog Monotherapy

Key Glaucoma Posters:

• Mark J. Gallardo, MD
  Safety of Travoprost Intraocular Implant Administration on the Corneal Endothelium
• Fritz H. Hengerer, MD
  Trabecular Micro-Bypass + Cataract Surgery Shows 7-Year Efficacy and Safety in Both Combined and Stand-Alone Usage
• Daniel J. Hu, BA
  Efficacy of Combined Trabecular Micro-Bypass and Goniotomy in Patients With OAG
• Joshua Kim, MD
  IOP Controlled in Greater Percentage of Subjects with Travoprost Intraocular Implant Compared with Topical Timolol at 3 Years
• Steven R. Sarkisian, MD
  Safety of the Surgical Exchange Procedure of Travoprost Intraocular Implant
• I. Paul Singh, MD
  Travoprost Intraocular Implant Demonstrates Noninferiority to Twice-Daily Timolol 0.5% in Lowering IOP

Key Corneal Health Presentations:

Friday, November 3, 2023, at 1:53 p.m. PT

• Theo Guenter Seiler, MD
  Innovations in Collagen Cross-Linking

Key Corneal Health Posters:

• Julia Yu
  Dynamics of Corneal Swelling During Hypotonic Riboflavin in Corneal Collagen Cross-Linking for Progressive Keratoconus Patients

Abstract information can be found at www.aao.org/annual-meeting.

The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry. All educational content of the AAO Annual Meeting is planned by its program committee, and AAO does not endorse, promote, approve or recommend the use of any products, devices or services.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.